Testosterone Cypionate
Strength: 250 mg/1 ml
Quantity: 10 ml
Active substance: Testosterone Cypionate
Manufacturer: Genesis
Testosterone Cypionate is a long-acting injectable testosterone commonly used in testosterone replacement therapy (TRT) to treat men with low testosterone levels. It is also widely used in bodybuilding for its powerful anabolic effects, which promote muscle growth, strength, and recovery.
- Active Ingredient: Testosterone cypionate, typically available at 200–250 mg per ml.
- Form: Oil-based injectable solution, administered intramuscularly.
- Mechanism: Testosterone cypionate has a long half-life (about 8 days), allowing for a sustained release of testosterone into the bloodstream. This slow-release mechanism makes it ideal for maintaining stable blood levels with less frequent dosing.
- Primary Uses: Prescribed primarily for TRT to address symptoms of low testosterone, such as low energy, reduced libido, muscle loss, and mood changes. In bodybuilding, it’s used to increase muscle mass, strength, and recovery.
Administration: Generally administered every 1–2 weeks, depending on medical guidance and individual needs.
Effects:
- Testosterone cypionate improves energy levels, libido, mood, and muscle mass, enhancing overall well-being and physical performance. It also aids in bone density maintenance and supports cardiovascular health in those with low testosterone.
Precautions and Side Effects:
- Possible side effects include water retention, acne, mood swings, gynecomastia (breast tissue growth), and changes in cholesterol levels. Long-term use may affect cardiovascular health.
- May suppress natural testosterone production, so post-cycle therapy (PCT) is recommended after prolonged use.
Note: Testosterone cypionate should only be used under medical supervision, especially for TRT, to monitor for any adverse effects and ensure safe and effective treatment. Misuse or overuse can lead to serious health issues, including hormonal imbalances and cardiovascular risks.
Reviews
There are no reviews yet.